LataMed AI Corp. (OTC: LMED), a healthcare technology company focused on Latin America, announced a memorandum of understanding with Venezuelan pharmacy chain FARMASER to develop a customized artificial intelligence and automation platform. The collaboration aims to support FARMASER’s current operations and planned expansion, potentially integrating LataMed’s AI-supported healthcare technologies across the pharmacy network.
The MOU outlines plans for the design, adaptation, testing, and evaluation of a software platform tailored to FARMASER’s operational requirements. The parties will begin defining technical and operational specifications, adapting the software to pharmacy workflows, and establishing a phased development process. The platform is expected to include e-commerce, prescription management, customer service, inventory planning, and business analytics functions.
A key component of the proposed platform is the potential integration of LataMed’s CardioAI, PulmoAI, and NeuroAI models across FARMASER’s three existing locations and up to 15 planned additional pharmacies. These AI-supported platforms are designed to assist healthcare professionals in evaluating cardiovascular, pulmonary, and neurological health information. However, the company emphasized that any prescription-related or AI-supported functionality would be designed to assist administrative and healthcare workflows, not replace professional judgment.
“This memorandum of understanding represents an opportunity to apply our technology within an important part of the healthcare delivery ecosystem,” said Dr. Kevin Rodan Levy, CEO of LataMed AI Corp. “Pharmacies play a central role in connecting patients with medications, healthcare products, and related services. Our objective is to work with FARMASER to develop a platform that supports its current operations and planned expansion.”
The parties are also evaluating an annual software licensing or subscription model for commercial implementation. However, the scope, timing, pricing, and other terms have not been finalized and remain subject to successful development, testing, and definitive agreements.
Management believes the collaboration aligns with LataMed’s broader strategy of building an integrated healthcare ecosystem connecting patients, healthcare professionals, pharmacies, insurers, and payment providers. The proposed platform represents a potential enterprise application beyond its patient-facing telemedicine services, creating technology infrastructure that may be adaptable to other healthcare organizations across Latin America.
The MOU establishes a cooperation framework but does not guarantee successful completion, commercial deployment, or revenue generation. The company will provide updates as appropriate. For additional information, visit https://latamed.ai or review SEC filings at www.sec.gov.
Forward-looking statements in this release involve risks and uncertainties, including the ability to develop and test the platform, satisfy technical requirements, agree on commercial terms, obtain financing, and comply with regulations. There is no assurance that the platform will be completed, that AI technologies will be integrated, or that additional FARMASER locations will open.
